Britain and America have established a important trade agreement that will guarantee zero tariffs on UK pharmaceutical exports entering the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the NHS. This pledge secures that duties on these key exports will remain at nothing for a period of three years.
This development follows recent threats to dramatically increase duties on patented pharmaceutical imports, with figures mentioned up to 100%.
"This arrangement between the Britain bolsters the worldwide climate for innovative medicines and brings long-overdue fairness to transatlantic pharmaceutical trade," an announcement noted.
Trade Importance
Medicines are one of the UK's largest goods shipped to the United States, which is easily the largest buyer for major UK drugmakers.
Export figures show that in the one-year period to the end of the third quarter, the UK exported medicines totaling billions to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards employment, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several key pledges from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must return to the NHS to prevent overspending will be restricted at 15%. Last year, refunds were more than twenty percent.
Recent Tensions
The deal follows a ongoing tension between the drug companies and the ministers over spending levels and approval rates.
This friction were heightened by assertions that American customers were charged several times more for the same drugs than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
